| 1. |
|
|
| 2. |
|
|
| 3. |
- Andreasson, Erik, et al.
(author)
-
The MAP kinase substrate MKS1 is a regulator of plant defence responces
- 2005
-
In: EMBO Journal. - : Wiley. - 1460-2075 .- 0261-4189. ; 24:14, s. 2579-2589
-
Journal article (peer-reviewed)abstract
- Arabidopsis MAP kinase 4 (MPK4) functions as a regulator of pathogen defense responses, because it is required for both repression of salicylic acid (SA)-dependent resistance and for activation of jasmonate (JA)-dependent defense gene expression. To understand MPK4 signaling mechanisms, we used yeast two-hybrid screening to identify the MPK4 substrate MKS1. Analyses of transgenic plants and genome-wide transcript profiling indicated that MKS1 is required for full SA-dependent resistance in mpk4 mutants, and that overexpression of MKS1 in wild-type plants is sufficient to activate SA-dependent resistance, but does not interfere with induction of a defense gene by JA. Further yeast two-hybrid screening revealed that MKS1 interacts with the WRKY transcription factors WRKY25 and WRKY33. WRKY25 and WRKY33 were shown to be in vitro substrates of MPK4, and a wrky33 knockout mutant was found to exhibit increased expression of the SA-related defense gene PR1. MKS1 may therefore contribute to MPK4-regulated defense activation by coupling the kinase to specific WRKY transcription factors.
|
|
| 4. |
- Andreasson, Ulf, 1968, et al.
(author)
-
Aspects of beta-amyloid as a biomarker for Alzheimer's disease
- 2007
-
In: Biomarkers in Medicine. - : Future Medicine Ltd. - 1752-0363 .- 1752-0371. ; 1:1, s. 59-78
-
Research review (peer-reviewed)abstract
- Alzheimer’s disease is an age-related neurodegenerative disorder that results in progressive cognitive impairment and death. The accumulation of β-amyloid (Aβ) in specific brain regions is believed by many to represent the earliest event in the pathogenesis of the disease. Here, we review the key aspects of Aβ as a biomarker for Alzheimer’s disease, including the pathogenicity of Aβ, the possible biological functions of its precursor protein, the Aβ metabolism and homeostasis, the diagnostic performance of different Aβ assays in different settings and the potential usefulness of Aβ as a surrogate marker for treatment efficacy in clinical trials of novel Aβ-targeting drugs against Alzheimer’s disease.
|
|
| 5. |
- Bardh, Ulla, 1936-
(author)
-
Församlingen som sakrament : Dop, medlemskap och ekumenik bland frikyrkokristna vid 1900-talets slut
- 2008
-
Doctoral thesis (other academic/artistic)abstract
- In the dissertation Free Church ecclesiology is examined from the point of view of three themes: faith, baptism and membership with certain concern for ecumenical experience.The essential source material in the dissertation consists of 30 qualified interviews with members from five Swedish Free Church denominations. The result of these interviews have been related to a broader Free Church context in history and the contemporary situation.In connection with these considerations a thesis about the congregation as a kind of sacrament has been applied to the material, specifically what relates to the significance of being a member of the congregation. The congregation as life form is verified through the congregation’s fellowship/communio as expressed in participation. This becomes an effective sign and instrument for the presence of Christ through the congregation in the world. The process of unity occurring within Swedish Free Church life is related to a mutual interpretation of the congregation as participant in the presence and work of Christ. The continouous process toward unity which has taken place between Free Church denominations with respect to distinctive teaching, not the least concerning baptism, along with praxis and spirituality is interpreted from such participation of the congregation in Christ’s presence and work.
|
|
| 6. |
- Brinkmalm-Westman, Ann, 1966, et al.
(author)
-
Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.
- 2009
-
In: Frontiers in bioscience : a journal and virtual library. - : IMR Press. - 1093-4715. ; 14, s. 1793-806
-
Research review (peer-reviewed)abstract
- Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.
|
|
| 7. |
- Caspersen, Mikael B., et al.
(author)
-
Phosphorylation sites of Arabidopsis MAP kinase substrate 1 (MKS 1)
- 2007
-
In: Biochimica et Biophysica Acta - Proteins and Proteomics. - : Elsevier BV. - 1570-9639. ; 1774:9, s. 1156-1163
-
Journal article (peer-reviewed)abstract
- The Arabidopsis MAP kinase 4 (MPK4) substrate MKS1 was expressed in Escherichia coli and purified, full-length, 6x histidine (His)-tagged MKS1 was phosphorylated in vitro by hemagglutinin (HA)-tagged MPK4 immuno-precipitated from plants. MKS1 phosphorylation was initially verified by electrophoresis and gel-staining with ProQ Diamond and the protein was digested by either trypsin or chymotrypsin for maximum sequence coverage to facilitate identification of phosphorylated positions. Prior to analysis by mass spectrometry, samples were either desalted, passed over TiO2 or both for improved phosphopeptide detection. As MAP kinases generally phosphorylate serine or threonine followed by proline (Ser/Thr-Pro), theoretical masses of potentially phosphorylated peptides were calculated and mass spectrometric peaks matching these masses were fragmented and searched for a neutral-loss signal at similar to 98 Da indicative of phosphorylation. Additionally, mass spectrometric peaks present in the MPK4-treated MKS1, but not in the control peptide map of untreated MKS1, were fragmented. Fragmentation spectra were subjected to a MASCOT database search which identified three of the twelve Ser-Pro serine residues (Ser72, Set108, Ser120) in the phosphorylated form.
|
|
| 8. |
- Clausen, Anders Ranegaard, et al.
(author)
-
A multisubstrate deoxyribonucleoside kinase from plants.
- 2008
-
In: Nucleic acids symposium series. - : Oxford University Press (OUP). - 0261-3166 .- 1746-8272. ; :52, s. 489-490
-
Journal article (peer-reviewed)abstract
- Deoxyribonucleoside kinases catalyze the rate limiting step during the salvage of deoxyribonucleosides and convert them into the corresponding monophosphate compounds. We have identified and characterized a unique multisubstrate deoxyribonucleoside kinase from plants. The phylogenetic relationship and biochemical properties suggest that this deoxyribonucleoside kinase represents a living fossil resembling the progenitor of the modern animal deoxycytidine, deoxyguanosine and thymidine 2 kinases. The broad substrate specificity makes this enzyme an interesting candidate to be evaluated as a suicide gene in anti-cancer therapy.
|
|
| 9. |
- Haumann, M, et al.
(author)
-
Bromide does not bind to the Mn4Ca complex in its S-1 state in Cl--depleted and br(-)-reconstituted oxygen-evolving photosystem II: Evidence from X-ray absorption spectroscopy at the BrK-edge
- 2006
-
In: Biochemistry. - : American Chemical Society (ACS). - 0006-2960 .- 1520-4995. ; 45:43, s. 13101-13107
-
Journal article (peer-reviewed)abstract
- Chloride is an important cofactor in photosynthetic water oxidation. It can be replaced by bromide with retention of the oxygen-evolving activity of photosystem II ( PSII). Binding of bromide to the Mn4Ca complex of PSII in its dark-stable S-1 state was studied by X-ray absorption spectroscopy ( XAS) at the Br K-edge in Cl--depleted and Br--substituted PSII membrane particles from spinach. The XAS spectra exclude the presence of metal ions in the first and second coordination spheres of Br-. EXAFS analysis provided tentative evidence of at least one metal ion, which may be manganese or calcium, at a distance of similar to 5 angstrom to Br-. The native Cl- ion may bind at a similar distance. Accordingly, water oxidation may not require binding of a halide directly to the metal ions of the Mn complex in its S-1 state.
|
|
| 10. |
- Henriksson, Roger, et al.
(author)
-
High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
- 2006
-
In: Journal of neuro-oncology. - : Springer Science and Business Media LLC. - 0167-594X .- 1573-7373. ; 78:3, s. 321-6
-
Journal article (peer-reviewed)abstract
- Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma. The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV. The 140 patients included were in a good clinical condition with a median age of 55 years (range 22-87). Estramustine was given orally, 280 mg twice daily, as soon as the diagnosis was established, during and after the radiotherapy for a period of in total 3 months. Radiotherapy was delivered on weekdays 2 Gy daily up to 56 Gy. Eighteen patients were excluded due to misclassification, leaving 122 patients eligible for evaluation. Overall the treatment was well tolerated. Mild or moderate nausea was the most common side effect of estramustine. The minimum follow-up time was 5.2 years for the surviving patients. For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group. In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively. Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively. In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively. Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups. No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol. In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
|
|
